Drug intelligence / Profile preview

paliroden

Development stage: Phase 2
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

Paliroden is an orally active neurotrophic small molecule compound that stimulates the synthesis of endogenous neurotrophins. Preclinical studies indicate that it increases the formation of both neural progenitors and mature neurons. Paliroden is a non-peptidic agent and has been investigated for its potential use in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease[6][8]. Its mechanism involves activation of neurotrophin synthesis rather than direct neurotransmitter receptor modulation.

Other names: palirodenepalirodenopalirodenum

Beyond the preview

Go deeper on paliroden.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paliroden.

Explore the full profile